Inside Health Policy covers our comment

Our comment to FDA about its use of the Pharmacy Compounding Advisory Committee (PCAC) was covered in detail by Inside Health Policy in “Compounding Pharmacies Say FDA Mismanages Compounding Ad Comm.”

Related posts

The Reuters story, “Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on...

Over the last few weeks, with the FDA declaring the end of the GLP-1 shortages, APC’s reporter...

Since the FDA announced that tirzepatide is (for now) out of shortage, APC’s Scott Brunner has been...